scholarly journals The pattern of allopurinol prescription in a university hospital practice

2020 ◽  
Vol 47 (1) ◽  
Author(s):  
Sahar Ahmed Saad ◽  
Maha Mahmoud Sabkar
Keyword(s):  
Uric Acid ◽  
Side Effects ◽  
Adverse Effects ◽  
Serum Uric Acid ◽  
Research Work ◽  
University Hospital ◽  
Hospital Practice ◽  
Inappropriate Use ◽  
The Cost

Abstract Background Allopurinol as a drug is commonly used to treat gout and its complications. The aim usually is to lower the level of serum uric acid. Also, it was found to be prescribed in cases of asymptomatic hyperuricemia. However, this medication has serious side effects and some of these are fatal. So the aim of the current research work is to look at its use, whether properly indicated or not, in a university hospital. Results A total of 427 patients were included in this study. Only 3.7% (16) of the patients had the drug for significant hyperuricemia. Gout was confirmed in 40 (9.4%) patients. Conclusion It is clear that most patients received allopurinol without proper indications. The inappropriate use of allopurinol should be looked at to reduce the cost of medication and more importantly to avoid possible adverse effects.

scholarly journals Prevalence of Hyperuricemia and the Relationship Between Serum Uric Acid Concentrations and Lipid Parameters Among King Abdulaziz University Hospital Patients

2021 ◽  
Author(s):  
Ranya A. Ghamri ◽  
Tala A. Qalai ◽  
Raghad A. Ismail ◽  
Joud M. Aljehani ◽  
Dina S. Alotaibi ◽  
...  
Keyword(s):  
Uric Acid ◽  
Lipid Profile ◽  
Serum Uric Acid ◽  
Acid Concentration ◽  
Density Lipoprotein ◽  
University Hospital ◽  
Uric Acid Concentration ◽  
Serum Uric Acid Concentration ◽  
King Abdulaziz University ◽  
The Relationship

Abstract Background: Hyperuricemia is a metabolic defect caused by high purine consumption, overproduction of uric acid, or reduced uric acid excretion. Hyperuricemia is the second most common metabolic disease after diabetes mellitus and can mediate proinflammatory endocrine imbalance in adipose tissue, which contributed to dyslipidemia. Furthermore, several studies have associated uric acid with dyslipidemia. However, no previous studies have examined patients without chronic illness. Thus, we aimed to assess the relationship between serum uric acid concentration and lipid profile parameters and to estimate the prevalence of hyperuricemia in the city of Jeddah. Methods: A retrospective study was conducted among 1206 patients without chronic illness after applying the exclusion criteria. Patients had undergone laboratory blood testing over a 3-year period (2018–2020) at King Abdulaziz University Hospital, which was ethically approved. We used a predesigned checklist to collect data from electronic hospital records using Google Forms. Bivariate analysis, tables, and graphs were used to represent and identify the relationships between variables. A P-value of <0.05 was considered significant.Results: Our study revealed a prevalence of 12% for hyperuricemia in the study population. Males were more frequently affected than females (8.13% vs. 3.73%, respectively). There was no association between serum uric acid concentration and lipid profile parameters, including total cholesterol (P = 0.92), triglyceride (P = 0.42), high-density lipoprotein (P = 0.47), and low-density lipoprotein (P = 0.66). There was a strong association between serum uric acid concentration and high body mass index (P < 0.001), older age (P = 0.002), male sex (P < 0.001), and nationality (P < 0.001). Furthermore, there was an association between sex and mean erythrocyte sedimentation rate (P = 0.02) and mean triglyceride concentration (P = 0.02).Conclusion: We observed a low prevalence of hyperuricemia, and our results indicate no association between serum uric acid concentration and lipid profile parameters.

scholarly journals Serum Uric Acid and Left Ventricular Mass in Essential Hypertension

2020 ◽  
Vol 7 ◽  
Author(s):  
Valeria Visco ◽  
Antonietta Valeria Pascale ◽  
Nicola Virtuoso ◽  
Felice Mongiello ◽  
Federico Cinque ◽  
...  
Keyword(s):  
Uric Acid ◽  
Left Ventricular Mass ◽  
Serum Uric Acid ◽  
Kidney Function ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
University Hospital ◽  
Ventricular Mass ◽  
Severe Chronic Kidney Disease ◽  
Independent Association

Serum uric acid (sUA) has been associated with cardiovascular risk. Although the recent mechanistic hypothesis poses the basis for the association between sUA and left ventricular mass index (LVMi), the issue remains poorly investigated in a clinical setup. Through a retrospective analysis of the database of the departmental Hypertension Clinic of University Hospital of Salerno Medical School, we identified 177 essential hypertensives (age 60.3 ± 13.3 years; 85 men), free from uric acid-modulating medications and severe chronic kidney disease, and whose sUA values, anthropometric, clinical, and echocardiographic data were available. In the studied cohort, the average duration of hypertension was 8.4 ± 7.1 years. LVMi associated with classical determinants, such as age, blood pressure, and kidney function, although after multivariate correction, only age remained significant. Also, sUA correlated positively with LVMi, as well as body size, metabolism, and kidney function. In a multivariate analysis, sUA confirmed the independent association with LVMi. Also, levels of sUA &gt;5.6 mg/dl are associated with larger cardiac size. We confirmed our data in a replicate analysis performed in a larger population (1,379 hypertensives) from an independent clinic. Our results demonstrate that sUA increases with LVMi, and a cutoff of 5.6 mg/dl predict larger LV sizes. Our data suggest that hyperuricemia might help to stratify the risk of larger cardiac size in hypertensives.

Asymptomatic Hyperuricaemia and its Early Treatment

1980 ◽  
Vol 8 (1) ◽  
pp. 95-97
Author(s):  
W A McDonald Scott
Keyword(s):  
Uric Acid ◽  
Adverse Effects ◽  
Serum Uric Acid ◽  
Early Treatment ◽  
Laboratory Tests

Sixteen patients with asymptomatic hyperuricaemia were treated with ‘Citro-Soda®”, an urinary alkanlinizing agent, in a dose of 4 g four times daily for one month. Ten of the sixteen patients exhibited a meaningful reduction in serum uric acid (> 15%). No adverse effects were noted and various haematological and urinary laboratory tests were all normal. ‘Citro-Soda®’ could, therefore, be considered a useful and well-tolerated adjunct in the treatment of hyperuricaemia.

scholarly journals Hyperuricemia in Systemic Hypertension and its correlation with systolic and diastolic blood pressure.

2020 ◽  
Vol 27 (01) ◽  
pp. 89-93
Author(s):  
Haji Khan Khoharo ◽  
Ali Akbar Shah ◽  
Fatima Qureshi ◽  
Sajjad Ali Almani
Keyword(s):  
Blood Pressure ◽  
Uric Acid ◽  
Diastolic Blood Pressure ◽  
Serum Uric Acid ◽  
Study Design ◽  
Venous Blood ◽  
University Hospital ◽  
Systemic Hypertension ◽  
Cross Sectional ◽  
Positive Correlation

Objectives: To determine the serum uric acid (SUA) in systemic hypertension and its correlation with systolic (SBP) and diastolic blood pressure (DBP). Study Design: Cross sectional study design. Setting: Department of Medicine, Isra University Hospital. Period: From April 2016 – February 2017. Material and Methods: A sample of 100 cases of systemic hypertension and 100 age, gender, body weight and BMI controls were selected through non-probability purposive sampling. Volunteers were asked for history, physical examination, and blood sampling. Systemic BP was measured with a mercury sphygmomanometer. 2 ml venous blood was taken, centrifuged and sera were used for detection of SUA. Data was saved in a pre- structured Performa. Computed based statistical software (SPSS v 22.0, IBM, Incorporation, USA) was used for data analysis. Data variables were analyzed at 95% CI (P ≤ 0.05). Results: Serum uric acid in controls was 2.91±0.75 mg/dl compared to 5.70±1.76 mg/dl (P=0.0001). 57% of cases revealed hyperuricemia compared to 11% in control (X2=17.5, P=0.0001). Serum Uric acid showed significantly positive correlation with Systolic BP (r= 0.518*, p=0.0001) and Diastolic BP (r= 0.397**, p=0.0001). Conclusion: The present study reports hyperuricemia in 57% cases of systemic hypertension and uric acid shows positive correlation with systolic and diastolic blood pressure.

Outcome of Febuxostat treatment in hyperuricemic pre-dialysis chronic kidney disease patients

2020 ◽  
Vol 7 (2) ◽  
pp. 45-52
Author(s):  
Dineshowri Shrestha ◽  
Anil Baral ◽  
Kashyap Dahal ◽  
Juju Raj Shrestha ◽  
Rajani Hada
Keyword(s):  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Adverse Effects ◽  
Serum Uric Acid ◽  
Kidney Injury ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Mdrd Equation ◽  
Ckd Stage

Introduction: Hyperuricemia is a cause and effect of chronic kidney disease (CKD), accelerates its progression and predisposes to acute kidney injury. Present study aimed to find out the outcome of Febuxostat treatment in hyperuricemic pre-dialysis CKD patients. Method: This was a cross sectional study conducted in Nephrology department, Bir hospital, Nepal, during from February 2019 to January 2020, among pre-dialysis CKD stage 3-5 non dialysis (ND) patients with serum uric acid (SUA) >7 mg/d L who were treated with Febuxostat 40 mg once a day and followed up at one, two and three months. The baseline SUA, creatinine, estimated glomerular filtration rate (eGFR) calculated by the modification of diet in renal disease (MDRD) equation compared with values at follow up and according to CKD stages. The adverse effects and liver enzymes were recorded. Result: There were total 50 patients, mean age 54.2±16.5 years, male 31 (62%).There were significant reductions of SUA from baseline of 8.9±1.4to 7.1±1.2 vs 5.9±0.9 vs 4.7±1.0) at one, two and three month respectively, p=0.000 and increment of eGFR (ml/min/1.73m2) from 29.6±15.0 to 31.6±16.0, 33.6±16.6, 34.1±17.1, p=0.000.And 41 (82%) patients achieved uric acid < 6 mg/dl at three month. Significant reduction of uric acid in all CKD stages and increment of eGFR in CKD stage 3 and 4 were observed. Adverse effects were epigastralgia in 5 (10%) and joint pain in 13 (26%). Conclusion: Febuxostat is an effective serum uric acid lowering drug in pre-dialysis chronic kidney disease patients with improvement of kidney function.

Piroxicam in the Treatment of Acute Gout: A Multicentre Open Study in General Practice

1979 ◽  
Vol 7 (6) ◽  
pp. 507-510 ◽  
Author(s):  
J Eric Murphy
Keyword(s):  
General Practice ◽  
Uric Acid ◽  
General Practitioner ◽  
Side Effects ◽  
Pain Relief ◽  
Serum Uric Acid ◽  
Open Study ◽  
Acute Gout ◽  
Highly Effective

Twenty-nine patients with acute gout were treated with piroxicam (40 mg daily for 5 days) in a multicentre general practitioner study. Pain relief was noticeable within 4 hours of the first dose and thereafter proceeded steadily, together with the early relief of other sypmtoms associated with acute gout. The prompt relief of symptoms was accompanied by a fall in serum uric acid. Piroxicam was well tolerated, eight patients experiencing side-effects that were mainly mild and gastro-intestinal in nature. The drug seems to be highly effective and safe in the treatment of acute gout.

scholarly journals The Effect of pncA Gene Mutation of Mycobacterium Tuberculosis to Transaminase and Uric Acid Serum in MDR TB Patient

2018 ◽  
Vol 38 (3) ◽  
pp. 150-157
Author(s):  
Yeni Vera ◽  
Bintang YM Sinaga ◽  
Dedi Ardinata ◽  
Yahwardiah Siregar
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Uric Acid ◽  
Side Effects ◽  
Gene Mutation ◽  
Serum Uric Acid ◽  
Serum Transaminase ◽  
Pcr Rflp ◽  
Mdr Tb ◽  
Quasi Experimental ◽  
The Common

Bacground: The common side effects of PZA treatment is the occurrence of hepatotoxicity and blocking the secretion of uric acid. This study aims to determine the effect of the pncA gene mutation of Mycobacterium tuberculosis to serum transaminase and serum uric acid in patients with MDR TB who had receive therapy with PZA. Methods: Quasi-experimental test was conducted at MDR TB polyclinic in H. Adam Malik Medan Hospital of 25 patients with MDR TB. Mutations of genes was assessed by PCR-RFLP method and data of serum transaminase and serum uric acid retrieved from the medical records, between February until June 2015 Result: Thirtysix percent pncA gene mutation founded. Significance statistic test between mutation of pncA gene and SGOT serum in baseline Vs 4 weeks (P=0,007), baseline Vs 8 weeks (P=0,023) and uric acid serum baseline Vs 4 weeks (P=0,011). No statistically difference in SGPT serum. No correlation between pncA gene (mutation and no mutation) with transaminase serum and uric acid serum. Conclusion: Transaminase serum and uric acid elevated in MDR TB patient with mutation in pncA gene.Mutation in pncA gene have a correlation with elevated SGOT serum compared between baseline, 4 and 8 weeks. No correlation between pncA gene mutation and SGPT. Mutation in pncA gene have a correlation with uric acid serum elevated in 4 weeks. No correlation between pncA gene (mutation and no mutation) with transaminase serum and uric acid serum elevated.

RAMADAN FASTING – EFFECT ON HEALTHY MUSLIMS

2004 ◽  
Vol 32 (1) ◽  
pp. 13-18 ◽  
Author(s):  
Masahiro Toda ◽  
Kanehisa Morimoto
Keyword(s):  
Mental Health ◽  
Weight Loss ◽  
Uric Acid ◽  
Health Status ◽  
Adverse Effects ◽  
Serum Uric Acid ◽  
Mental Health Status ◽  
Healthy Individuals ◽  
Ramadan Fasting ◽  
Lipid Parameters

The purpose of this review was to ascertain the effects on healthy Muslims of fasting during Ramadan. We found some changes such as weight loss, evidence of dehydration, increase in serum uric acid, and nonpharmacological improvement in lipid parameters. We also observed changes in daily lifestyles and mental-health status. Thus, observance of the Ramadan fasting has both positive and adverse effects on healthy individuals. The adverse effects, however, are unlikely to persist after Ramadan or to lead to other complications. Healthy individuals can observe Ramadan without anxiety about their health.

The gut microbiota mediates the protective effects of anserine supplementation on hyperuricaemia and associated renal inflammation

2021 ◽  
Author(s):  
Jiaojiao Han ◽  
Ziyan Wang ◽  
Chenyang Lu ◽  
Jun Zhou ◽  
Ye Li ◽  
...  
Keyword(s):  
Uric Acid ◽  
Side Effects ◽  
Gut Microbiota ◽  
Serum Uric Acid ◽  
Acid Content ◽  
Elevated Serum ◽  
Protective Effects ◽  
Renal Inflammation

Hyperuricaemia is a disease associated with elevated serum uric acid content, which has emerged rapidly in recent decades. The drugs used to treat clinical hyperuricaemia have side effects, and their...

Sign in / Sign up

Export Citation Format

Share Document